| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 11.30B | 11.17B | 9.35B | 10.03B | 10.45B | 7.36B |
| Gross Profit | 4.22B | 4.25B | 2.58B | 3.46B | 4.55B | 2.69B |
| EBITDA | 1.25B | 1.58B | 579.65M | 1.04B | 1.81B | 500.81M |
| Net Income | 470.50M | 911.88M | -408.66M | 45.29M | 1.55B | 87.12M |
Balance Sheet | ||||||
| Total Assets | 16.32B | 15.93B | 15.98B | 16.20B | 14.61B | 11.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.36B | 2.41B | 2.69B | 2.61B | 2.39B | 3.02B |
| Total Debt | 6.13B | 5.34B | 6.37B | 6.01B | 4.09B | 5.11B |
| Total Liabilities | 8.13B | 7.47B | 8.49B | 8.20B | 6.52B | 6.93B |
| Stockholders Equity | 8.19B | 8.46B | 7.48B | 8.00B | 8.09B | 4.37B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 915.12M | -178.77M | -1.42B | -1.70B | -375.25M |
| Operating Cash Flow | 0.00 | 1.60B | 451.87M | -423.12M | 1.66B | -114.49M |
| Investing Cash Flow | 0.00 | -695.59M | -633.76M | -1.07B | -3.34B | -225.17M |
| Financing Cash Flow | 0.00 | -1.06B | 144.43M | 1.64B | 932.90M | 575.07M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ¥134.02B | 11.39 | ― | 3.72% | 5.40% | 14.80% | |
76 Outperform | ¥90.80B | 12.64 | ― | 3.04% | 1.57% | -33.97% | |
75 Outperform | ¥740.87B | 21.12 | 12.15% | 1.58% | 2.62% | 2.81% | |
75 Outperform | ¥12.63B | 22.74 | ― | 2.29% | 5.37% | 63.30% | |
75 Outperform | ¥619.65B | 39.14 | ― | 3.26% | 11.78% | 8.98% | |
68 Neutral | ¥2.35T | 18.48 | 11.98% | 1.54% | 1.84% | -6.57% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% |
Mipox Corporation reported consolidated net sales of ¥8.87 billion for the nine months ended December 31, 2025, up 6.7% year on year, but operating profit fell 48.8% to ¥428 million, with profit attributable to owners of parent down 46.1% to ¥431 million. Despite higher sales, profit margins weakened significantly, though the balance sheet remained solid with total assets of ¥17.35 billion and an equity ratio of 50.6%.
The company kept its dividend policy unchanged, paying no interim dividend but planning a year-end dividend of ¥10 per share, matching the prior year’s total. For the full year to March 31, 2026, Mipox forecasts net sales of ¥11 billion, a slight 1.5% decline, and a sharp profit contraction, with operating profit expected to drop 36.3% and net profit 39.7%, signaling ongoing pressure on earnings despite stable top-line performance.
The most recent analyst rating on (JP:5381) stock is a Buy with a Yen875.00 price target. To see the full list of analyst forecasts on Mipox Corp. stock, see the JP:5381 Stock Forecast page.
Mipox Corporation reported consolidated net sales of ¥5.69 billion for the six months ended September 30, 2025, up 1.1% year on year, but operating profit plunged 63.1% to ¥235 million and profit attributable to owners of parent fell 42.0% to ¥265 million, reflecting a sharp deterioration in profitability despite marginal top-line growth; total assets increased to ¥17.29 billion while the equity ratio weakened to 48.8% from 53.1%. The company kept its interim dividend at zero and reaffirmed a full-year dividend of ¥10 per share, while revising its earnings forecast for the year ending March 31, 2026 to project a slight decline in annual sales to ¥11.0 billion and steep drops in profit, signaling a more challenging operating environment and potentially softer returns for shareholders compared with the prior year.
The most recent analyst rating on (JP:5381) stock is a Hold with a Yen487.00 price target. To see the full list of analyst forecasts on Mipox Corp. stock, see the JP:5381 Stock Forecast page.